Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
WebcastFaculty
OVERVIEW
Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices is organized by National Association for Continuing Education (NACE) and will be held during Feb 01, 2017 - Jan 31, 2018.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Description:
This monograph reviews the benefits, risks, and appropriate use of oral anticoagulants, with a focus on issues relevant to the primary care setting.
The new class of direct oral anticoagulants (DOACs) does not require therapeutic monitoring and has demonstrated reduced risk for intracranial hemorrhage compared to warfarin. But these agents too have their drawbacks, including risk for gastrointestinal (GI) bleeding and the lack of specific reversal agents for most DOACs. As a result of these and other challenges, oral anticoagulation is widely underused, leaving many patients with AF at elevated risk for stroke and mortality.
Conference Objectives are:
• Identify those patients at risk for cardioembolic stroke who are appropriate candidates for anticoagulation.
• Recognize common misperceptions about anticoagulation risk to improve communication and patient adherence.
• Discuss the management of bleeding in patients on anticoagulants.
• Describe the role of continued anticoagulation in the setting of emerging non-pharmacologic therapy.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Description:
This monograph reviews the benefits, risks, and appropriate use of oral anticoagulants, with a focus on issues relevant to the primary care setting.
The new class of direct oral anticoagulants (DOACs) does not require therapeutic monitoring and has demonstrated reduced risk for intracranial hemorrhage compared to warfarin. But these agents too have their drawbacks, including risk for gastrointestinal (GI) bleeding and the lack of specific reversal agents for most DOACs. As a result of these and other challenges, oral anticoagulation is widely underused, leaving many patients with AF at elevated risk for stroke and mortality.
Conference Objectives are:
• Identify those patients at risk for cardioembolic stroke who are appropriate candidates for anticoagulation.
• Recognize common misperceptions about anticoagulation risk to improve communication and patient adherence.
• Discuss the management of bleeding in patients on anticoagulants.
• Describe the role of continued anticoagulation in the setting of emerging non-pharmacologic therapy.
Additional details will be posted as soon as they are available.
SPECIALITIES
CardiologyRELATED ONLINE COURSES
Quick Links